DDInter1837 DDInter1658
Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Toremifene {u} (Compound) resembles {v} (Compound) Doxylamine
Toremifene {u} (Compound) treats {v} (Disease) breast cancer
Toremifene {u} (Compound) binds {v} (Gene) ABCB1
Toremifene {u} (Compound) upregulates {v} (Gene) SQSTM1
Toremifene {u} (Compound) downregulates {v} (Gene) PMM2
Toremifene {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Toremifene {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aprepitant
Toremifene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metolazone
Toremifene {u} may lead to a major life threatening interaction when taken with {v} Pazopanib
Toremifene (Compound) resembles Doxylamine (Compound)
Toremifene (Compound) treats breast cancer (Disease)
Toremifene (Compound) binds ABCB1 (Gene)
Toremifene (Compound) upregulates SQSTM1 (Gene)
Toremifene (Compound) downregulates PMM2 (Gene)
Toremifene (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Metolazone
Toremifene may lead to a major life threatening interaction when taken with Pazopanib